danicopan

complement factor D inhibitor

Also Known As:

(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide; ACH-0144471; ACH-4471

Networked: 6 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Huang, Mingjun: 3 articles (12/2021 - 01/2017)
2.	Browett, Peter: 2 articles (12/2021 - 11/2021)
3.	Geffner, Michael: 2 articles (12/2021 - 11/2021)
4.	Kulasekararaj, Austin G: 2 articles (12/2021 - 11/2021)
5.	Lee, Jong Wook: 2 articles (12/2021 - 11/2021)
6.	Maciejewski, Jaroslaw P: 2 articles (12/2021 - 11/2021)
7.	Notaro, Rosario: 2 articles (12/2021 - 11/2021)
8.	Risitano, Antonio M: 2 articles (12/2021 - 11/2021)
9.	Brodsky, Robert A: 2 articles (11/2021 - 01/2017)
10.	Brodsky, Robert: 1 article (12/2021)

Related Diseases

1.	Hemolysis 01/01/2017 - "Additionally the compound ACH-4471 significantly decreased C3 fragment deposition on paroxysmal nocturnal hemoglobinuria erythrocytes, indicating a reduced potential relative to eculizumab for extravascular hemolysis. " 12/01/2023 - "These primary efficacy and safety results show that danicopan as add-on treatment to ravulizumab or eculizumab significantly improved haemoglobin concentrations at week 12 with no new safety concerns, suggesting an improved benefit-risk profile in patients with PNH and clinically significant extravascular haemolysis. " 12/01/2023 - "Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial." 12/01/2023 - "The aim of this study was to assess the efficacy and safety of danicopan (ALXN2040), an investigational, first-in-class, oral complement factor D inhibitor, as add-on therapy to ravulizumab or eculizumab in patients with PNH and clinically significant extravascular haemolysis. "
2.	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 11/18/2021 - "Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab." 12/01/2021 - "Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria" 01/01/2017 - "Additionally the compound ACH-4471 significantly decreased C3 fragment deposition on paroxysmal nocturnal hemoglobinuria erythrocytes, indicating a reduced potential relative to eculizumab for extravascular hemolysis. "
3.	Membranoproliferative Glomerulonephritis (Membranoproliferative Glomerulonephritis, Type II) 01/01/2022 - "We present two phase 2 proof-of-concept clinical studies of the orally active FD inhibitor danicopan in patients with C3G and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) (NCT03369236 and NCT03459443). "
4.	Geographic Atrophy 10/03/2022 - "These findings suggest that oral danicopan possesses potential for treating geographic atrophy because AP dysregulation in the posterior segment of the eye is reported to be involved in the disease pathogenesis."
5.	Abdominal Pain (Pain, Abdominal) 12/01/2023 - "The serious adverse events reported in the danicopan group were cholecystitis (one [2%] patient) and COVID-19 (one [2%]) and in the placebo group were anaemia and abdominal pain, both in one (4%) patient. "

Related Drugs and Biologics

1.	eculizumab
2.	ravulizumab
3.	Complement Factor D (Factor D)
4.	Antigen-Antibody Complex (Immune Complex)
5.	Aspartate Aminotransferases (Aspartate Transaminase)
6.	Alanine Transaminase (SGPT)

Related Therapies and Procedures

1.	Therapeutics